open access
Vol 58, No 1 (2024)
Response to Letter to the Editors
Submitted: 2023-11-18
Accepted: 2023-11-20
Published online: 2023-12-19
Get Citation
Updates on pharmacological treatment for Alzheimer’s disease: response to Letter to the Editors
1
Affiliations- Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States
open access
Vol 58, No 1 (2024)
Responses to Letter to the Editors
Submitted: 2023-11-18
Accepted: 2023-11-20
Published online: 2023-12-19
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Updates on pharmacological treatment for Alzheimer’s disease: response to Letter to the Editors
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Response to Letter to the Editors
Pages
142-143
Published online
2023-12-19
Page views
238
Article views/downloads
198
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2024;58(1):142-143.
Authors
Philip W. Tipton
References (6)- Tipton PW. Updates on pharmacological treatment for Alzheimer's disease. Neurol Neurochir Pol. 2023 [Epub ahead of print].
- Gaggero G, Taietti D, Parrella V. Cerebral amyloid angiopathy associated with Alzheimer's disease: two pathologies from a single peptide? Neurol Neurochir Pol. 2023; [Epub ahead of print].
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023; 388(1): 9–21.
- Sims JR, Zimmer JA, Evans CD, et al. TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6): 512–527.
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023; 10(3): 362–377.
- Leurent C, Goodman JA, Zhang Y, et al. Ponezumab Trial Study Group. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol. 2019; 6(4): 795–806.
